Abstract
Navacaprant, a Novel Kappa Opioid Receptor Antagonist for Major Depressive Disorder: A Randomized Placebo-Controlled Phase 2 Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.biopsych.2024.02.031
Journal: Biological Psychiatry | Publication Date: May 1, 2024 |
Navacaprant, a Novel Kappa Opioid Receptor Antagonist for Major Depressive Disorder: A Randomized Placebo-Controlled Phase 2 Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have